Eftilagimod alfa shows promise as a novel immunotherapy for head and neck cancer patients with low PD-L1 expression, offering ...

The FDA reviews odronextamab's application for relapsed lymphoma, highlighting trial enrollment issues but confirming safety and efficacy.

During a live event, Barbara T. Ma, MD, MS, examined trial data on lifileucel tumor infiltrating lymphocyte therapy in ...

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

An expert highlights how optimizing CAR T-cell therapy requires simplifying the treatment process, reducing insurance delays, addressing that 40% to 50% of patients may need further therapy, managing ...

An expert explains that T-cell fitness is critical for CAR T-cell therapy success, as earlier use—before multiple rounds of chemotherapy or bispecific antibody exposure—helps preserve T-cell quality ...

An expert discusses that while CAR T-cell therapies carry risks such as cytokine release syndrome and neurotoxicity, advancements in supportive care and monitoring have significantly improved their ...

Allogene Therapeutics halts ALLO-647 trial in large B-cell lymphoma after a patient death raises safety concerns, impacting ...

Cardiff Oncology reveals promising results for onvansertib in treating KRAS- or NRAS-mutated metastatic colorectal cancer, ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Trethera Corporation initiates a clinical trial for TRE-515, exploring its potential in oncology and autoimmune diseases ...